Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

PerkinElmer Completes Sale of Medical Imaging Business to Varex Imaging

PerkinElmer Inc., a global leader committed to innovating for a healthier world, announced that the company has completed the sale of its Medical Imaging business to Varex Imaging Corporation.

Read More »

Caribou Biosciences and DuPont Pioneer Develop New Method to Comprehensively Map the Off-Target Activity of CRISPR-Cas9 Across Entire Genomes

Caribou Biosciences Inc. announced the Nature Methods publication describing SITE-Seq, a new method for comprehensively mapping CRISPR-Cas9 cleavage sites across the genome of any organism. When compared against other off-target analysis techniques, SITE-Seq detected potential off-target cleavage sites with a higher degree of resolution.

Read More »

Widespread Vitamin D Deficiency Likely Due to Sunscreen Use, Increase of Chronic Diseases

  Study in The Journal of the American Osteopathic Association Highlights Risk Factors, Treatment Protocols     CHICAGO, May 1, 2017 /PRNewswire-USNewswire/ –Results from a clinical review published in The Journal of the American Osteopathic Association find nearly 1 billion people worldwide may have deficient or insufficient levels of vitamin D due to chronic disease […]

Read More »

Neurotrope Alzheimer’s drug data fails to impress; shares crater

Neurotrope Inc. said on Monday that the smaller dose of its experimental Alzheimer’s drug met the main goal in a small mid-stage study, but the company’s shares more than halved as investors were not impressed with the data.

Read More »

GlaxoSmithKline Injects $139 Million in Maryland Expansion

London-based GlaxoSmithKline announced that it is investing $139 million into its manufacturing location in Rockville, Md.

Read More »

Kala Pharmaceuticals Announces Positive Results from Confirmatory Phase 3 Trial of KPI-121 1% Following Cataract Surgery

Kala Pharmaceuticals Inc. today announced positive top-line results from its confirmatory Phase 3 trial of KPI-121 1% for the treatment of inflammation and pain in patients who have undergone cataract surgery.

Read More »

Agreement Reached After Novo Nordisk A/S is Accused of Disguising Salespeople and Dealing Kickbacks

Danish drugmaker Novo Nordisk A/S has settled a U.S. Department of Justice probe into the company’s marketing activities for its diabetes drugs that allegedly included paybacks to doctors and disguising sales people as medical educators, Bloomberg reported.

Read More »

Tiny Parion Sciences Seals Dry Eye Drug Deal Worth $535 Million With Biotech Giant Shire

North Carolina-based Parion Sciences snagged a deal worth up to $535 million from Shire for its experimental dry eye disease treatment, P-321.

Read More »

Takeda’s $5 Billion Bet On Ariad Pays Off With Accelerated Approval Of Lung Cancer Med

The U.S. Food and Drug Administration granted Takeda Pharmaceutical’s Alunbrig (brigatinib) accelerated approval for anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in patients who have progressed on or are intolerant to crizotinib.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!


Ad Right Bottom